Alzamend Neuro Achieves Nasdaq Listing Compliance

Alzamend Neuro, a clinical-stage biopharmaceutical company, has announced it is now compliant with Nasdaq's minimum stockholders' equity requirement. The company's recent quarterly report demonstrated stockholders' equity of over $5.8 million, surpassing the $2.5 million threshold. This resolution addresses a previous non-compliance issue, securing its continued listing on the Nasdaq exchange.